Typically, mean costs and mean measures of effectiveness are used in the estimation of the incremental cost effectiveness ratio (ICER). Cost and effectiveness distributions, however, are often skewed. The goal of this work is to use a nonparametric generalization of location to obtain a location region in the cost effectiveness plane. The region accounts for uncertainty and all points in the region are appropriate estimates of the ICER that account for skewness in the marginal distributions. METHODS: First, analogous to Mann-Whitney, all pairwise cost and effectiveness treatment differences are computed. Using univariate methods, an estimate of a location rectangle is obtained as the Cartesian product of marginal location intervals, intervals that account for skewness. By considering the intersection of such rectangles over all orthogonal transformations, a closed convex region is obtained. This method will then be applied to simulated bivariate cost effectiveness data using both symmetric and skewed distributions. KolmogorovSmirnov provides simultaneous confidence bands for each univariate rectangle. Any point of this region is an estimate of the ICER; all such points satisfy basic axioms of bivariate location. This approach will also be used to construct a generalization of the cost effectiveness acceptability curve with uncertainty incorporated. A test for marginal skewness can precede the construction of the location region. RESULTS: By comparing the location region with the usual bootstrap estimates for the ICER, it was found that the location region approach produced confidence intervals that were considerably larger for both skewed and symmetric distributions of costs and effectiveness. CONCLUSIONS: This work provides estimates of the ICER that appropriately accounting for skewness. In such cases, the mean is not the best measure of location. In spite of the used of the nonparametric bootstrap to obtain confidence intervals, skewness introduces an extra element of variability that should be accounted for.
OBJECTIVES:
To show how the discrete modelling of continuously varying doseresponse relationships in cost-effective analysis (CEA) influences incremental cost-effectiveness ratios (ICERs), cost-effectiveness acceptability curves (CEACs) and the expected value of perfect information (EVPI). In particular, to show that each of these metrics is contingent on the discrete comparisons chosen within a CEA. METHODS: The cost-effectiveness of a hypothetical intervention with a continuous dose-response relationship is simulated. The cost-effectiveness of a small number of possible dose levels is simulated first. The analysis is then repeated a number of times, progressively increasing the number of possible doses and resulting combinations of costs and effects. For each run of the analysis ICERs are calculated for each dose level, a probabilistic sensitivity analysis is simulated, and CEACs and the EVPI are plotted. RESULTS: As the number of potential cost and effect combinations increases, the ICERs for each dose level increase, the CEACs fall towards zero and the EVPI both rises and changes from having sharp inflection points to being a smooth, downward-sloping curve. CONCLUSIONS: Many interventions demonstrate dose-response relationships, most of which are in principle continuous, even if doses are typically varied discretely. The continuously increasing intensity of interventions means the number of possible alternatives is infinite. The general conclusion from the analysis is that each of the metrics presented here are contingent on the discrete comparisons chosen within the analysis. The significance of this finding for CEACs depends on their interpretation, which varies in the literature. The significance for EVPI is that while it has previously been recognised that excluding relevant comparators can reduce the EVPI, including all theoretically relevant alternatives may be impossible. Further work may be required to understand this constraint on measuring the upper bound of the value of further research. 
PRM38 THE EXTENSION OF THE COST-EFFECTIVENESS

OBJECTIVES:
To develop new schemes which can make the cost-effectiveness acceptability curve (CEAC) augmented to be more informative regarding the types of acceptance and statistical inference. METHODS: Theoretical approaches have been undertaken to address two questions: how the area under the curve (AUC) can be zoned by the types of acceptance, and how the accepted dataset of incremental cost-effectiveness ratios (ICERs), which are generated by computer runs, can be statistically associated with a standard threshold of ICER. RESULTS: The AUC of a typical sigmoid-shaped CEAC was divided into three zones, each of which represents the proportion, p i ϭ n i / n( 0 ), where n i is the number of plots on the costeffectiveness plain belonging to the quadrant i (iϭ1:South-East, 2:North-East and 3:South-West), and n( 0 ) is the total number of plots (i.e., n( 0 )ϭn 1 ϩn 2 ϩn 3 ) accepted for the threshold, 0 , of ICER. A solution for the second question was "a new CEAC of the mean (MCEAC)", which can be constructed by plotting a pair of m 0 and p 0 instead of a pair of 0 and p 0 , where 0 : the threshold of ICER for acceptance, p 0 : the probability of acceptance for the threshold 0 , and m 0 : the mean ICER of all the plots accepted for the threshold 0 . Also, statistical validity of the MCEAC was inferred by the confidence interval of the mean m 0 using t-test. Furthermore, the series of confidence intervals defined for one threshold 0 corresponding to different size of computer runs were summarized as a diagram for showing the progression of the confidence intervals, which looks similar to the forest plot in metaanalysis. All those schemes were graphically illustrated based on examples. CONCLUSIONS: Visualizing the component types of acceptance in the AUC, drawing the MCEAC, and the progression diagram of confidence intervals will provide us with more useful information on cost-effectiveness decisions. 
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PRM39 LITERATURE REVIEW OF RANDOMIZED, CONTROLLED STUDIES OF THE IMPACT OF PHARMACISTS' INTERVENTIONS TO IMPROVE PATIENT OUTCOMES
OBJECTIVES:
The objective was to summarize the impact of pharmacists' interventions on patient outcomes as reported in studies utilizing a randomized controlled trial (RCT) design. METHODS: A comprehensive literature search was conducted utilizing PubMed and International Pharmaceutical Abstracts for the years 1979-2009. Studies were included if they evaluated pharmacist-provided interventions, utilized RCT designs with control groups, and were conducted in the United States. Studies were summarized by 1) publication year; 2) study setting; 3) disease/health condition; and 4) type of intervention provided and whether performed by a pharmacist alone or a pharmacist with other health care professionals, 5) primary outcome variables and 6) study findings. Patient outcome results were categorized as 'positive', if they found a statistically significant improvement in the patient outcomes when compared to the control group, or 'no difference' if no significant difference was found. RESULTS: Of the 552 citations reviewed, 100 studies met the inclusion criteria. The numbers of pharmacists' intervention studies conducted using RCT designs increased from 1979 to 2009, with 64% conducted after 2000. The majority of the studies were conducted in clinic setting (65%) followed by community pharmacies (19%), hospitals (12%), home-care (2%), and multiple settings (2%). Chronic conditions were studied in 56% of the studies. Studies of interventions delivered by pharmacists alone comprised 64%, while 36% involved pharmacists working with other health care providers. Overall, 'positive' patient outcomes were demonstrated in 73% of the studies. When interventions were delivered by pharmacists working with other health care providers, however, 97.2% had positive outcomes. CONCLUSIONS: 'Positive' patient outcomes were demonstrated in the majority of the studies, supporting increased pharmacists' roles in the health care system to improve patient outcomes. When working alongside other health care providers, the positive impact was most likely. 
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PRM40 ISSUES CONCERNING THE TRANSLATION OF THE WORD 'HASSLED' IN THE MORISKY MEDICATION ADHERENCE SCALE (MMAS-8)
OBJECTIVES:
The word 'hassle' is commonly used in PRO measures including the Morisky Medication Adherence Scale (MMAS-8). The translation of the word 'hassle' is used as an example of how creation of a concept elaboration and a full translation and linguistic validation process can result in a translation that is conceptually equivalent to the source text and to aid in the future translation of ambiguous words. METHODS: The MMAS-8 was translated into 29 languages using the standard methodology of two forward translations, reconciliation, two back translations, back-translation review, developer review and proofreading. Examples of translation issues of the word 'hassled' in the following statement were assessed: Do you ever feel hassled about sticking to your anti-rejection treatment plan? RESULTS: A 'hassle' is defined in the Oxford English Dictionary as an 'irritating inconvenience'. In the above question, this word encompasses several conceptsbothered, troubled, disturbed -which were provided to translators in a concept elaboration document. The translation process resulted in the following: The initial French translation was back-translated as bothered/annoyed. Alternatives backtranslating as 'preoccupied' and 'inconvenient' were suggested but rejected. The developer piloted the final suggestion, debordé (overwhelmed), with Frenchspeaking students, who agreed that this was the best translation in this context. For other languages, 'hassled' was translated variously as: a nuisance, cumbersome, difficult, bothersome, troubling, tiresome, irksome, burdensome and complicated. These were queried with translator and the developer to confirm concep-A152 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4 
